A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital.

J Surg Oncol 2015 Feb 6;111(2):203-7. Epub 2014 Oct 6.

Instituto Nacional de Cancerología, Mexico City, Mexico.

Background: The majority of breast cancer patients in Mexico are treated through the public health system and >80% receive adjuvant chemotherapy. The aim of this prospective study was to characterize the impact of the Oncotype DX assay on adjuvant therapy decision making and the confidence in those decisions amongst public sector physicians in Mexico.

Methods: Ninety-eight consecutive patients with ER+, HER2-, stage I-IIIa, N0/N1-3 node-positive breast cancer from the Instituto Nacional de Cancerología were eligible for the study. The primary endpoint was the overall change in treatment recommendations after receiving the assay results.

Results: Of 96 patients, 48% received a chemohormonal therapy recommendation prior to testing. Following receipt of results, treatment decisions changed for 31/96 (32%) patients, including 17/62 (27%) node-negative patients and 14/34 (41%) node-positive patients. The proportion of patients with a chemotherapy-based recommendation decreased from 48% pre- to 34% post-assay (P=0.024). 92% of physicians agreed that they were more confident in their treatment recommendation after ordering the assay.

Conclusions: These results suggest that use of the 21-gene assay in the Mexican public health system has a meaningful impact on adjuvant treatment recommendations that may reduce the overall use of chemotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.23794DOI Listing
February 2015
65 Reads

Publication Analysis

Top Keywords

breast cancer
16
adjuvant chemotherapy
8
assay adjuvant
8
health system
8
treatment recommendations
8
mexican public
8
public health
8
patients
7
study primary
4
nacional cancerología
4
34% post-assay
4
cancerología eligible
4
eligible study
4
pre- 34%
4
48% pre-
4
recommendations receiving
4
change treatment
4
treatment
4
primary endpoint
4
endpoint change
4

References

(Supplied by CrossRef)
Atlas of the health systems of Latin America
Dantés et al.
Salud Publica Mex 2011
Identification of malignant breast lesions in Mexico
López-Carrillo et al.
Salud Publica Mex 2001
Available resources for the treatment of breast cancer in Mexico
Mohar et al.
Salud Publica Mex 2009
The costs of breast cancer in a Mexican public health institution
Gómez-Rico et al.
Risk Manag Healthc Policy 2008
Polychemotherapy for early breast cancer: An overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group et al.
Lancet 1998

Similar Publications